COVID-19 Clinical Trial
Official title:
Prospective Randomized Double Blind Placebo Controlled Study of Efficacy of the Therapy With BRAINMAX® Using Functional Magnetic Resonance Imaging (fMRI) for the Treatment of Patients With Post-COVID Asthenic Syndrome
Verified date | July 2023 |
Source | Promomed, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID asthenic syndrome.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 20, 2022 |
Est. primary completion date | December 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 50 Years |
Eligibility | Inclusion Criteria: - Patients able to sign the patient informed consent form for the participation in the clinical study - Patients of both sexes of 25-50 years of age - Patient's negative test result for severe acute respiratory syndrome (SARS) -CoV-2 RNA obtained by polymerase chain reaction (PCR) method within 72 hours - COVID-19 diagnosis documented in the history more than 12 weeks ago* - Symptoms of Post-COVID-19 syndrome (asthenic state, feeling of energy loss and decreased functioning, intellectual function disorder, attention and memory disorder, emotional lability, reducing stress resistance) which appeared during or after COVID-19, retain for more than 12 weeks and cannot be explained by an alternative diagnosis - Patients capable of following the requirements of the Clinical Study Protocol - Negative pregnancy test result (for women with the active childbearing potential) - MFI-20 scale score is more than 30 at the moment of screening. - Higher education. - Lack of decompensated somatic pathology - Lack of indications of the transferred/current disease of the nervous system Exclusion Criteria: - Allergic reactions to the components of the study product - Taking prohibited drugs/dietary supplements during the previous randomization of the month - Severe hepatic failure - Severe renal failure - Chronic liver and hepatic diseases - Thyroid diseases - Anaemia - Malignant tumour of any localization currently or during 5 years before the inclusion into the study except for completely treated carcinoma in situ - Autoimmune diseases - Other chronical diseases which, according to the investigator, can cause asthenia - Pregnancy or lactation period - Tuberculosis, cancers or positive reaction to the HIV infection, hepatitis B & C, syphilis according to the history data - Severe eyesight and/or hearing disorders, serious articulation disorders and/or other deviations able to prevent the patient from adequate cooperation during the study) - Mental disorders in the history - Alcohol, drug abuse or drug dependence in the history - Patients which, according to the investigator, are obviously or probably incapable of understanding and evaluating this study information within the process of the informed consent form signing, including but not limited to with regard to expected risks and possible discomfort - Other diseases, symptoms or conditions not listed above, which, according to the investigator, are predicaments for the participation in the clinical study - The presence of contraindications for MRI - The presence of contraindications for taking the drug Contraindications for MRI: - Electronic medical devices in the body (cardiomyostimulator and other) - Metal elements in the study area (prosthesis, clamp, fragment) - Invariable behavior of patients - Inability to remain still during MRI Prohibited drugs/dietary supplements: - Ethyl methyl hydroxypyridine succinate and Meldonium (other than the one studied in the study) - Psychotropic medication - Drugs containing succinic acid and its salts - Drugs containing vitamin B6 and /or its derivatives - Antioxidants, antihypoxic drug and metabolic drugs - Nootropic drugs |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal State Budgetary Research Institution "Research Centre of Neurology" | Moscow |
Lead Sponsor | Collaborator |
---|---|
Promomed, LLC |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changing patterns of brain activation using task fMRI with a cognitive paradigm | Changing patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking Brainmax in comparison with placebo in patients with post-COVID asthenic syndrome. | From baseline to Visit 2 (day 10) | |
Secondary | Asthenia on a scale Multidimensional Fatigue Inventory (MFI-20) after the completion of the parenteral therapy | MFI-20 has an even proportion of positively and negatively worded items that are rated on a 5-point Likert scale. Subscale scores (range 4-20) are calculated as the sum of item ratings and a total fatigue score (range 20-100) is calculated as the sum of subscale scores. Higher scores indicate a higher level of fatigue.
Mean decrease of MFI-20 asthenia scale score after the completion of the parenteral therapy |
From baseline to Visit 2 (day 10) | |
Secondary | Fatigue on a Fatigue Assessment Scale (FAS-10) scale after the completion of the parenteral therapy | The FAS is a 10-item general fatigue questionnaire to assess fatigue. Five questions reflect physical fatigue and 5 questions (questions 3 and 6-9) mental fatigue. Subsequently, the total FAS score can be calculated by summing the scores on all questions (recoded scores for questions 4 and 10). The total score ranges from 10 to 50. A total FAS score < 22 indicates no fatigue, a score = 22 indicates fatigue.
Score dynamics by FAS-10 scale after the completion of the parenteral therapy |
From baseline to Visit 2 (day 10) | |
Secondary | Cognitive function on a Montreal Cognitive Assessment (MoCA) scale after the completion of the parenteral therapy | The Montreal Cognitive Assessment (MoCA) is a test used by healthcare providers to evaluate people with memory loss or other symptoms of cognitive decline. Scores on the MoCA range from zero to 30. A score of 26 and higher is considered normal.
Score dynamics by MoCA scale after the completion of the parenteral therapy |
From baseline to Visit 2 (day 10) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|